Xalud Therapeutics, Inc.
- Country
- πΊπΈUnited States
- Ownership
- Holding
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.xaludthera.com
Safety Study of XT-150 in Participants With ALS
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Xalud Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06704347
- Locations
- πΊπΈ
Barrow Neurological Institute (St. Joseph's), Phoenix, Arizona, United States
πΊπΈJohns Hopkins University, Baltimore, Maryland, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain
- Conditions
- Facet Joint PainBack PainInflammation
- Interventions
- Biological: Placebo
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Xalud Therapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT05196919
- Locations
- πΊπΈ
Neurovations, Napa, California, United States
πΊπΈSource HealthCare, Santa Monica, California, United States
πΊπΈCenter for Clinical Research, Winston-Salem, North Carolina, United States
Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis
- Conditions
- Osteoarthritis, Spine
- Interventions
- Biological: XT-150
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Xalud Therapeutics, Inc.
- Registration Number
- NCT04841512
- Locations
- π¦πΊ
Alfred Health, Melbourne, Victoria, Australia
Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain
- Conditions
- Neuropathic Pain
- Interventions
- Biological: XT-150Biological: Placebo
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Xalud Therapeutics, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04466410
- Locations
- π¦πΊ
Genesis Research Services, Newcastle, New South Wales, Australia
π¦πΊCerCare, Wayville, South Australia, Australia
π¦πΊAlfred Health, Melbourne, Victoria, Australia
Efficacy and Safety of XT-150 in Osteoarthritis of the Knee
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Xalud Therapeutics, Inc.
- Target Recruit Count
- 289
- Registration Number
- NCT04124042
- Locations
- πΊπΈ
Neurovations (Napa Pain Institute), Napa, California, United States
πΊπΈeStudySite, La Mesa, California, United States
πΊπΈCarolinas Clinical Research Institute, Winston-Salem, North Carolina, United States
Follow on Extension of XT-150-1-0201
- Conditions
- Osteoarthritis, Knee
- Interventions
- Biological: XT-150
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Xalud Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03769662
- Locations
- π¦πΊ
CMAX Clinical Research Pty Ltd in collaboration with University of Adelaide, Adelaide, South Australia, Australia
Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain
- Conditions
- Osteoarthritis, Knee
- Interventions
- Biological: XT-150
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Xalud Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03477487
- Locations
- πΊπΈ
Neurovations (Napa Pain Institute), Napa, California, United States
Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain
- Conditions
- Osteoarthritis, Knee
- Interventions
- Biological: XT-150
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Xalud Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03282149
- Locations
- π¦πΊ
CMAX Clinical Research Pty Ltd in collaboration with University of Adelaide, Adelaide, South Australia, Australia